The company, which is only three years removed from one of biotech’s most lucrative IPOs, will cut jobs for a third time and ...

For a small rare disease company with a treatment in the clinic, the toughest challenge isn’t necessarily the science. Often, ...

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...

A medicine built around a more precise form of CRISPR gene editing appeared to work as designed in its first clinical trial ...

The quality of digital PCR data can only be as high as the assays used to obtain it. High-quality assays ensure that the ...

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” ...

Patient advocates are hoping for change under new director Michelle Tarver, while industry groups hope she will build on ...

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...